TB006: Difference between revisions
Content deleted Content added
←Created page with ''''TB006''' is a humanized monoclonal antibody targeting galectin-3, which is suspected to be a factor in the formation of amyloid plaques.<ref>{{cite journal |last1=Cummings |first1=Jeffrey L. |last2=Osse |first2=Amanda M. Leisgang |last3=Kinney |first3=Jefferson W. |title=Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification |journal=Drugs |date=October 2023 |volume=83 |issue=15 |pages=1387–1408 |doi=10.1007/s40...' |
(No difference)
|
Revision as of 07:51, 7 December 2023
TB006 is a humanized monoclonal antibody targeting galectin-3, which is suspected to be a factor in the formation of amyloid plaques.[1][2][3]
References
- ^ Cummings, Jeffrey L.; Osse, Amanda M. Leisgang; Kinney, Jefferson W. (October 2023). "Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification". Drugs. 83 (15): 1387–1408. doi:10.1007/s40265-023-01938-w.
- ^ Rasool, Suhail; Patel, Pooja; Johansson, Jenny; Voloboueva, Ludmila; Lee, Sangmi; Sun, Jessica; Lan, Xi; Ahmed, Taufeeq; Sun, Dongxu (December 2022). "Potential Reversal of Alzheimer's Disease pathology by Antibody TB006 Targeting Galectin‐3, the Root Cause of Oligomerization of Amyloid Proteins". Alzheimer's & Dementia. 18 (S10). doi:10.1002/alz.060393.
- ^ Chaurasiya, Akash; Katke, Sumeet; Panchal, Kanan; Nirmal, Jayabalan (2023). "Biologics for the management of dementia". Nanomedicine-Based Approaches for the Treatment of Dementia: 193–234. doi:10.1016/B978-0-12-824331-2.00001-7.